Stock Analysis
Madrigal Pharmaceuticals, Inc. Common StockMDGL
Sector: Healthcare · Industry: Pharmaceutical Preparations
AnalystsStrong Buy24 analystsPrice is 20% of the way from the year's low to its high.
Cash covers 241% of debt · Q2 2026.
PMP Verdict
Cheap for a reason — weak fundamentals
Strengths
- Financial Health75
Risks
- Growth0
- Profitability0
Cheap for a reason — fundamentals remain weak.
Market context
-2.2% today· Z 1.8σ
Bull Case
- ✓Altman Z 9.3 — safe-zone balance sheet
What's happening with MDGL
Profile
Strong financial health; growth, profitability, moat, earnings quality and valuation lag behind.
How is each axis scored?
- Valuation32/100 · Weak
- P/E vs own history (n/a)10/25
- FCF yield (-2.0%)0/25
- P/S (8.1x)12/25
- EV/EBIT (n/a)10/25
- Growth0/100 · Weak
- Revenue CAGR (n/a)0/25
- Net income CAGR (n/a)0/25
- EPS CAGR 5Y (n/a)0/25
- Fwd implied growth (n/a)0/25
- Profitability0/100 · Weak
- ROIC (-778.9%)0/25
- ROE (-62.1%)0/25
- Net margin (-25.3%)0/25
- Operating margin (-25.1%)0/25
- Financial Health75/100 · Strong
- Altman Z (9.25)25/25
- Current ratio (3.20)25/25
- Interest coverage (-24.1x)0/25
- Net cash / debt (Net cash)25/25
- Quality5/100 · Weak
- Piotroski F (3/9)5/25
- Beneish M (0.14)0/25
- FCF conversion (n/a)0/25
- Margin stability (σ 656.5%)0/25
- Moat0/100 · Weak
- ROIC >12% years (n/a)0/25
- Median gross margin (n/a)0/25
- FCF-positive years (0/10 yrs)0/25
- Worst-year net margin (n/a)0/25
Risk Flags
- ⚠Beneish M 0.14 — earnings-manipulation flag
- ⚠Negative FCF margin (-0.2%) — burning cash
- ⚠SBC 9.5% of revenue — real dilution cost
- ⚠10 loss-making years in recent history
- ⚠Interest coverage -24.1× — thin debt cushion
About Madrigal Pharmaceuticals, Inc. Common Stock
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Show more
Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
Headquarters: WEST CONSHOHOCKEN, PA · Employees: 915 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
32DP/E (TTM)—
Price / TTM EPS (own statements)
P/FCF112.2xD
Grade D: ExpensivePrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield-2.0%D
Grade D: NegativeTTM (OCF − CapEx) / Market Cap — vs own 5Y history: -21.5%–-1.2% · 76th pct
P/S (TTM)8.05xC
Grade C: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 8.1x–54.9x · lowest in history
EV/EBITDA646.7xD
Grade D: ExpensiveEnterprise value / EBITDA (Finnhub) — capital-structure neutral
EV/Sales8.3xC
Grade C: ExpensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E148.1xD
Grade D: ExpensivePrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio19.74xD
Grade D: Very expensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio-125.27A
Grade A: CheapFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
0EROIC-778.9%D
Grade D: LowNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE-62.1%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA-25.5%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin-25.3%D
Grade D: LowNet Income / Revenue
Operating Margin-25.1%D
Grade D: LowTTM EBIT / TTM Revenue
Gross Margin91.5%A
Grade A: PremiumGross Profit / Revenue
FCF Margin-16.1%D
Grade D: LowFCF / Revenue
True FCF Margin-25.5%D
Grade D: LowTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
0ERevenue CAGR—
Compound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR—
Compound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)—
Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth—
Analyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)—
Share count change over 5Y
SBC / Net Income—
Stock-based comp/Net income. >30% = dilution risk
SBC / Revenue9.5%D
Grade D: HighTTM stock-based comp / TTM Revenue
Financial Health
75B+Altman Z-Score9.25A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio3.20xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio2.76xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage-24.1xD
Grade D: RiskyEBIT/Interest. >10 Strong
Debt RepaymentNet CashA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBIT1.5xA
Grade A: LowLeverage. <2x Low, >4x High
Debt/Equity0.66xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt2.41xA
Grade A: CoveredCash covers how much of total debt. >1 = could repay all debt from cash
Quality
5EPiotroski F-Score3/9D
Grade D: WeakFinancial strength 0–9. >7 Strong
Beneish M-Score0.14D
Grade D: RiskyEarnings manipulation risk. < -2.22 Safe
FCF Conversion—
FCF / Net Income
Margin Stability656.5%D
Grade D: VolatileEBIT margin std deviation. Lower = stable
Capex / Revenue0.7%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover1.01xA
Grade A: HighRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Sibold William John Filed | Sibold William John | SellOpen market sale | -120 | |
Sibold William John Filed | Sibold William John | SellOpen market sale | -761 | |
Sibold William John Filed | Sibold William John | SellOpen market sale | -1539 | |
Sibold William John Filed | Sibold William John | SellOpen market sale | -1202 | |
Sibold William John Filed | Sibold William John | SellOpen market sale | -368 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Sibold William John Filed | Sibold William John | SellOpen market sale | -687 | |
Sibold William John Filed | Sibold William John | SellOpen market sale | -160 | |
Sibold William John Filed | Sibold William John | SellOpen market sale | -218 |
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
0EROIC >12% Years—
Share of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)—
Median annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years0/10 yrsD
Grade D: WeakShare of completed fiscal years with positive free cash flow
Net Margin Floor—
Weakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)—
TTM net income per share (Finnhub fallback)
Cash / Share$36.32
Cash & short-term investments per share (Finnhub)
Book Value / Share$22.68
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$347.75M
Total debt obligations (short + long term)
Cash & Equiv.$838.75M
Cash and short-term investments
Net Debt$-491.00MA
Grade A: Net CashTotal Debt minus Cash. Negative = Net Cash position
Total Equity$523.72M
Shareholders' equity (book value)
Asset / Liability1.73xC
Grade C: AdequateTotal Assets / Total Liabilities
Market
Market Cap$10.34B
Current Market Capitalization
Beta-1.09B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Madrigal Pharmaceuticals, Inc. Common Stock (MDGL)
MDGL is down 2.19% at the last close. Madrigal Pharmaceuticals, Inc. Common Stock meets only 3 of 9 Piotroski F-Score criteria — a sign of weak underlying fundamentals. Altman Z-Score of 9.25 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Beneish M-Score of 0.14 is above the −1.78 flag threshold, a signal that reported earnings warrant closer scrutiny.
- Free-cash-flow margin is negative (-16%) — the business currently burns cash.
- Company is effectively debt-free after netting cash.
- Interest coverage of -24.1× leaves little room for earnings shocks.
- Madrigal Pharmaceuticals, Inc. Common Stock posted a net loss in 10 of 10 available completed fiscal years (2016–2025).
See how MDGL ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all MDGL moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 14 | Regular | 458.79 | +1.47% | 2.23 |
| Oct 14 | After-hours | 460.01 | +1.75% | 2.49 |
| Oct 13 | Regular | 454.20 | -2.77% | -2.35 |
| Oct 13 | After-hours | 452.12 | -3.22% | -2.83 |
Frequently Asked Questions about MDGL
What is the current Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) stock price?
MDGL is trading at $449.74 at the last market close, down 2.19% on the session. PreMarketPrice tracks MDGL pre-market, intraday and after-hours prices.
Is MDGL stock a buy right now?
PreMarketPrice's quantitative model rates Madrigal Pharmaceuticals, Inc. Common Stock's financial health at 75/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is MDGL stock overvalued?
Madrigal Pharmaceuticals, Inc. Common Stock trades at a trailing P/E of n/a and our valuation score rates it 32/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Madrigal Pharmaceuticals, Inc. Common Stock report earnings?
No confirmed earnings date is currently scheduled for MDGL. The Earnings section lists recent reports and updates as dates are announced.
What sector does Madrigal Pharmaceuticals, Inc. Common Stock operate in?
Madrigal Pharmaceuticals, Inc. Common Stock operates in the Healthcare sector, within the Pharmaceutical Preparations industry. The Related Stocks section lists sector peers for comparison.
What does Madrigal Pharmaceuticals, Inc. Common Stock do?
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality.
About Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) Stock
Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry. As of the latest update, Madrigal Pharmaceuticals, Inc. Common Stock is trading at $449.74, down 2.19% on the day with a market capitalization of $10.3 billion. The financial health score for MDGL is 75/100, which indicates excellent financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for MDGL stock.
MDGL Stock Analysis & Key Metrics
On PreMarketPrice, you can track Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) across multiple dimensions:
- Pre-market price & movement: Real-time MDGL stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for MDGL with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Madrigal Pharmaceuticals, Inc. Common Stock across multiple reporting periods.
- Financial health score: A composite score of 75/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for MDGL.
- Sector peers: Compare MDGL against 6 other healthcare stocks on key financial metrics.
Is MDGL a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) as an investment. The financial health score of 75/100 suggests excellent financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.